Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

por García‐Alfonso, Pilar, Benavides, Manuel, Falcó, Esther, Muñoz, Andrés, Gómez, Auxiliadora, Sastre, Javier, Rivera, Fernando, Montagut, Clara, Salgado, Mercedes, López‐Ladrón, Amelia, López, Rafael, Ruiz de Mena, Inmaculada, Durán, Gema, Aranda, Enrique
Publicado 2018

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

por Elez, Elena, Pericay, Carles, Valladares-Ayerbes, Manuel, Bando, Inmaculada, Safont, Maria Jose, Gallego, Javier, Grávalos, Cristina, Arrivi, Antonio, Carrato, Alfredo, Conde, Verónica, Ortiz, Maria José, López, Carlos, Alonso, Beatriz, Ruiz de Mena, Inmaculada, Díaz-Rubio, Eduardo, Tabernero, Josep, Aranda, Enrique
Publicado 2019